95 related articles for article (PubMed ID: 8879478)
1. Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic.
Cowley DS; Adams JB; Pyke RE; Cook J; Zaccharias P; Wingerson D; Roy-Byrne PP
Biol Psychiatry; 1996 Sep; 40(6):550-2. PubMed ID: 8879478
[No Abstract] [Full Text] [Related]
2. Single-site findings in a study of the safety and efficacy of a CCKB receptor antagonist, CI-988, in the treatment of generalized anxiety disorder.
Sramek JJ; Costa JF; Adams JB; Macpherson A; Cutler NR
Anxiety; 1994-1995; 1(5):242-3. PubMed ID: 9160582
[No Abstract] [Full Text] [Related]
3. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.
van Megen HJ; Westenberg HG; den Boer JA; Slaap B; van Es-Radhakishun F; Pande AC
Psychopharmacology (Berl); 1997 Feb; 129(3):243-8. PubMed ID: 9084062
[TBL] [Abstract][Full Text] [Related]
4. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.
Bradwejn J; Koszycki D; Paradis M; Reece P; Hinton J; Sedman A
Biol Psychiatry; 1995 Dec; 38(11):742-6. PubMed ID: 8580227
[TBL] [Abstract][Full Text] [Related]
5. [Suppression of conditioned fear by administration of CCKB receptor antagonist PD135158].
Tsutsumi T; Isogawa K; Kouno Y; Hikichi T; Nagayama H; Akiyoshi J
Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Feb; 18(1):15-8. PubMed ID: 9592807
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder.
Adams JB; Pyke RE; Costa J; Cutler NR; Schweizer E; Wilcox CS; Wisselink PG; Greiner M; Pierce MW; Pande AC
J Clin Psychopharmacol; 1995 Dec; 15(6):428-34. PubMed ID: 8748432
[TBL] [Abstract][Full Text] [Related]
7. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder.
Pande AC; Greiner M; Adams JB; Lydiard RB; Pierce MW
Biol Psychiatry; 1999 Sep; 46(6):860-2. PubMed ID: 10494457
[TBL] [Abstract][Full Text] [Related]
8. Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients.
van Megen HJ; Westenberg HG; den Boer JA
Biol Psychiatry; 1996 Oct; 40(8):804-6. PubMed ID: 8894076
[No Abstract] [Full Text] [Related]
9. Suppression of conditioned fear by administration of CCKB receptor antagonist PD135158.
Tsutsumi T; Akiyoshi J; Isogawa K; Kohno Y; Hikichi T; Nagayama H
Neuropeptides; 1999 Dec; 33(6):483-6. PubMed ID: 10657528
[TBL] [Abstract][Full Text] [Related]
10. Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists.
Hughes J; Hunter JC; Woodruff GN
Neuropeptides; 1991 Jul; 19 Suppl():85-9. PubMed ID: 1679213
[No Abstract] [Full Text] [Related]
11. Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients.
Pols H; Verburg K; Hauzer R; Meijer J; Griez E
Biol Psychiatry; 1996 Nov; 40(9):913-7. PubMed ID: 8896779
[TBL] [Abstract][Full Text] [Related]
12. Anxiogenic effects of Sumatriptan in panic disorder: a double-blind, placebo-controlled study.
Amital D; Fostick L; Sasson Y; Kindler S; Amital H; Zohar J
Eur Neuropsychopharmacol; 2005 May; 15(3):279-82. PubMed ID: 15820416
[TBL] [Abstract][Full Text] [Related]
13. Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs.
Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J
J Clin Psychopharmacol; 2006 Oct; 26(5):519-23. PubMed ID: 16974197
[TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder.
Kramer MS; Cutler NR; Ballenger JC; Patterson WM; Mendels J; Chenault A; Shrivastava R; Matzura-Wolfe D; Lines C; Reines S
Biol Psychiatry; 1995 Apr; 37(7):462-6. PubMed ID: 7786960
[TBL] [Abstract][Full Text] [Related]
15. Comparison of sodium lactate-induced panic symptoms between panic disorder and posttraumatic stress disorder.
Jensen CF; Peskind ER; Keller TW; McFall ME; Raskind MA
Depress Anxiety; 1998; 7(3):122-5. PubMed ID: 9656092
[No Abstract] [Full Text] [Related]
16. Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder.
Goddard AW; Woods SW; Money R; Pande AC; Charney DS; Goodman WK; Heninger GR; Price LH
Psychiatry Res; 1999 Mar; 85(3):225-40. PubMed ID: 10333376
[TBL] [Abstract][Full Text] [Related]
17. The effects of central cholecystokinin receptor blockade on hypothalamic-pituitary-adrenal and symptomatic responses to overnight withdrawal from alprazolam.
Abelson JL; Curtis GC; Nesse R; Fantone R; Pyke RE; Bammert-Adams J
Biol Psychiatry; 1995 Jan; 37(1):56-9. PubMed ID: 7893861
[No Abstract] [Full Text] [Related]
18. Cholecystokinin and panic disorder: past and future clinical research strategies.
Bradwejn J; Koszycki D
Scand J Clin Lab Invest Suppl; 2001; 234():19-27. PubMed ID: 11713976
[TBL] [Abstract][Full Text] [Related]
19. The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.
Lee JH; Dunner DL
Depress Anxiety; 2008; 25(2):91-7. PubMed ID: 17311265
[TBL] [Abstract][Full Text] [Related]
20. Relationship between anxiety and thyroid function in patients with panic disorder.
Kikuchi M; Komuro R; Oka H; Kidani T; Hanaoka A; Koshino Y
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):77-81. PubMed ID: 15610948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
